Last updated: August 12, 2026
UCB, Inc. sued Mylan Technologies Inc. in the U.S. District Court for the District of Utah over Mylan’s abbreviated new drug application for a generic rotigotine transdermal system, the generic equivalent of UCB’s Neupro patch. The action, docketed as Case No. 2:22-cv-00216, was a Hatch-Waxman patent dispute focused on UCB’s later-expiring formulation and transdermal-delivery patents. The case did not concern a biosimilar or biologic product.
What drug and product were involved in UCB v. Mylan?
The dispute involved rotigotine transdermal patches marketed by UCB as Neupro.
| Item |
Details |
| Brand |
Neupro |
| Active ingredient |
Rotigotine |
| Dosage form |
Transdermal patch |
| Therapeutic area |
Parkinson’s disease and restless legs syndrome |
| Reference sponsor |
UCB, Inc. |
| Proposed generic applicant |
Mylan Technologies Inc. |
| Regulatory pathway |
ANDA under the Hatch-Waxman Act |
| Case |
UCB, Inc. v. Mylan Technologies Inc., No. 2:22-cv-00216 |
| Court |
U.S. District Court for the District of Utah |
| Dispute type |
Patent infringement litigation based on Mylan’s ANDA filing |
Neupro delivers rotigotine through the skin over an extended period. Mylan Technologies was a relevant defendant because its business includes transdermal drug-delivery products and manufacturing capabilities.
What patents did UCB assert against Mylan?
UCB’s complaint asserted patents covering rotigotine transdermal systems and related product characteristics. The principal patents identified in the action were:
| Patent |
General subject matter |
Relevance |
| U.S. Patent No. 10,966,942 |
Rotigotine transdermal therapeutic system |
Later-expiring product and formulation protection |
| U.S. Patent No. 11,034,715 |
Rotigotine transdermal therapeutic system |
Additional protection for the patch structure and composition |
The case arose from Mylan’s Paragraph IV certification that the relevant UCB patents were invalid, unenforceable, or would not be infringed by Mylan’s proposed product. UCB treated the ANDA filing as an act of infringement under 35 U.S.C. § 271(e)(2).
The asserted patents were distinct from the older Neupro patents that supported the product’s initial market protection. UCB’s litigation strategy relied on later-filed patents to extend protection beyond the expiration of earlier foundational patents.
How did the Hatch-Waxman litigation begin?
Mylan submitted an ANDA seeking FDA approval for a generic rotigotine transdermal system. The Paragraph IV certification triggered UCB’s statutory right to file an infringement action within 45 days of receiving notice.
The filing of the lawsuit triggered the statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to earlier termination through a court decision, settlement, or other statutory event. During the stay, FDA approval of Mylan’s ANDA could be delayed even if the proposed product otherwise satisfied FDA requirements.
The central legal questions were:
- Whether Mylan’s proposed patch fell within the asserted patent claims.
- Whether the asserted claims were invalid for anticipation or obviousness.
- Whether the patents were enforceable.
- When Mylan could obtain FDA approval and commercially launch if it prevailed or settled.
What was the legal theory in UCB v. Mylan?
UCB’s case was a conventional ANDA patent-infringement action. The alleged infringement did not arise from commercial sales. It arose from Mylan’s submission of an ANDA seeking approval to manufacture, use, or sell a product allegedly covered by UCB’s patents.
Mylan’s Paragraph IV position placed the validity and scope of UCB’s later patent estate at issue. In a transdermal-patch case, the relevant claim limitations can include:
- The identity and amount of the active pharmaceutical ingredient.
- The adhesive matrix or other drug-containing layer.
- The relationship between the drug and adhesive components.
- Release characteristics.
- Patch dimensions and construction.
- Chemical stability during storage.
- Manufacturing parameters.
- Use of the patch for a claimed medical indication.
The technical dispute therefore extended beyond the rotigotine molecule itself. The older compound and basic transdermal delivery concepts were subject to earlier patent filings. UCB’s later patents had value only to the extent that their claim limitations captured Mylan’s specific patch design or manufacturing process.
What was the Orange Book status of Neupro?
Neupro’s Orange Book protection included patents directed to the product’s transdermal system rather than only to rotigotine as a chemical compound. FDA Orange Book listings are commercially important because they identify patents that an ANDA applicant must address through Paragraph I, II, III, or IV certification.
The Orange Book framework creates different risks depending on the listed patent:
| Patent category |
Generic-entry effect |
| Compound patent |
Can block broad product commercialization until expiration |
| Formulation patent |
Can require design-around or support Paragraph IV litigation |
| Delivery-system patent |
Particularly important for patches, implants, and extended-release systems |
| Method-of-use patent |
May permit a label carve-out, depending on the claimed indication |
| Manufacturing patent |
Can create process risk but may not block all product configurations |
For Neupro, the principal risk to Mylan was product-level infringement. A transdermal generic cannot easily avoid a formulation or delivery-system patent without changing the patch’s composition, performance, or manufacturing economics.
The Orange Book should be read together with the asserted claims and the FDA-approved labeling. Listing alone does not establish infringement or validity.
When does Neupro lose exclusivity?
Neupro’s exclusivity has several separate components:
- Regulatory exclusivity for the original NDA.
- Patent protection for rotigotine and early transdermal systems.
- Later formulation and delivery-system patents.
- Any pediatric-exclusivity extension.
- Litigation-related delay under the Hatch-Waxman statute.
Regulatory exclusivity and patent exclusivity are not interchangeable. FDA exclusivity may expire before the last Orange Book patent expires. A generic applicant can file an ANDA after regulatory exclusivity ends but may remain blocked by listed patents.
The UCB-Mylan litigation was significant because the asserted patents were later-generation patents. Their expiration dates extended materially beyond the earliest Neupro patent protection, creating a potential second patent barrier for generic rotigotine patches.
A precise commercial launch date could not be inferred solely from the case filing. It would depend on the final disposition, any settlement terms, the statutory stay, FDA approval, and whether Mylan secured an agreed launch date.
Did Mylan file a Paragraph IV challenge?
Yes. The lawsuit was based on Mylan’s Paragraph IV certification concerning UCB’s listed Neupro patents.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. It allows the ANDA applicant to challenge the patent before launch and gives the brand sponsor a basis to sue under the Hatch-Waxman statute.
Paragraph IV litigation creates two commercial paths:
- Mylan could prevail through a judgment of non-infringement or invalidity.
- UCB and Mylan could settle and establish a negotiated launch date or other commercialization terms.
The case record should be distinguished from a final merits judgment. A complaint and Paragraph IV certification establish a dispute, not a determination that either side’s patent position was correct.
What was the litigation status and outcome?
The action was filed in 2022 as an ANDA patent case concerning Mylan’s proposed rotigotine patch. The public docket reflects a patent dispute rather than a reported trial judgment establishing infringement or invalidity.
No reported Federal Circuit merits decision appears to have created binding precedent from this case. The commercial outcome therefore depends primarily on the docket disposition and any confidential or partially confidential settlement agreement.
In Hatch-Waxman cases, dismissal frequently follows a settlement. A dismissal alone does not disclose:
- The agreed generic launch date.
- Whether UCB granted a license.
- Whether Mylan paid or received consideration.
- Whether the agreement included supply, manufacturing, or authorized-generic terms.
- Whether the settlement was subject to FTC or Department of Justice review.
- Whether Mylan retained the right to launch after a patent invalidity event in separate litigation.
Unless the settlement agreement is filed publicly, the launch date and economic terms cannot be derived from the dismissal order alone.
Were there licensing deals or settlement agreements?
The public litigation record does not establish a disclosed commercial license comparable to a public asset-sale or co-development transaction. Any resolution between UCB and Mylan should be analyzed separately from a license.
A Hatch-Waxman settlement may include:
- A license to the asserted patents.
- A delayed generic-entry date.
- A waiver of further patent claims.
- A supply arrangement.
- An authorized-generic commitment.
- Restrictions on launch, manufacturing, or distribution.
- Terms allocating risk if another generic enters earlier.
The FTC has treated certain reverse-payment arrangements as potentially anticompetitive, but not every patent settlement is unlawful. The controlling analysis depends on the agreement’s economic terms, patent scope, and whether the settlement restricts competition beyond the exclusionary potential of the patent.
How strong was UCB’s patent estate?
UCB’s estate had moderate strategic strength because it combined older Neupro protection with later patents directed to the patch system. Its strength was not uniform across all patent categories.
Strengths
- UCB had product-specific patents rather than relying only on a broad compound claim.
- Rotigotine patches require a particular delivery format, limiting easy substitution.
- Mylan’s ANDA created a direct infringement theory before launch.
- Later patent terms could extend beyond the earliest Neupro patents.
Weaknesses
- Later formulation patents face obviousness challenges based on earlier patch technology.
- Patent claims must match Mylan’s precise formulation and manufacturing process.
- A generic applicant may avoid some method-of-use claims through a label carve-out.
- The asserted patents could be vulnerable to written-description, enablement, anticipation, or obviousness attacks.
- Earlier public disclosures concerning rotigotine patches could narrow the enforceable claim scope.
The most important technical issue was likely claim construction: whether the asserted patent limitations covered Mylan’s proposed patch as actually described in the ANDA.
What generic-entry risks existed for Neupro?
Mylan’s proposed entry presented several risks to UCB:
- Price erosion in Parkinson’s disease and restless-legs-syndrome markets.
- Pharmacy substitution after generic approval.
- Loss of patch-market share to Mylan and other ANDA applicants.
- Reduced value of later Orange Book patents.
- Manufacturing pressure on UCB’s transdermal supply chain.
- Increased litigation exposure from additional generic applicants.
Mylan also faced risks:
- An injunction or adverse infringement judgment.
- Delay under the 30-month stay.
- Required redesign of the patch.
- Higher manufacturing costs.
- Exposure to damages if it launched after an adverse judgment.
- Potential loss of first-filer or early-entry advantages.
Because Mylan Technologies has transdermal manufacturing expertise, its competitive position differed from that of a conventional oral-solid-dose generic company. The ability to reproduce the patch’s adhesion, drug release, stability, and manufacturing specifications was a commercial barrier independent of patent validity.
How did UCB’s Neupro estate compare with competing drug patents?
Neupro differs from oral Parkinson’s drugs because its principal product risk lies in drug-delivery technology. Oral products often depend on compound, salt, polymorph, dosage-form, and method-of-use patents. A transdermal product depends heavily on adhesive chemistry, patch architecture, release control, and manufacturing reproducibility.
| Product type |
Primary patent risk |
| Oral generic |
Compound, salt, polymorph, formulation, method of use |
| Transdermal generic |
Patch composition, adhesive matrix, release profile, manufacturing |
| Biologic |
Composition, process, formulation, regulatory exclusivity |
| Long-acting injectable |
Formulation, particle size, device, administration method |
Biosimilar risk was not relevant to this case because rotigotine is a small-molecule drug regulated through the ANDA pathway.
What is the business significance of UCB v. Mylan?
The case tested whether UCB could use later-generation transdermal patents to preserve Neupro exclusivity after earlier patent barriers weakened. For UCB, the value was tied to the size and timing of generic exposure. For Mylan, the value depended on securing approval for a technically complex patch and obtaining an entry date that justified the manufacturing investment.
The case also illustrates a recurring pharmaceutical strategy: extending product protection through formulation and delivery patents after the principal active-ingredient patents approach expiration. Such patents can be commercially effective, but their enforceability depends on detailed claim limitations and the strength of the prior-art record.
Key Takeaways
- UCB sued Mylan Technologies over an ANDA for generic rotigotine transdermal patches.
- The product was Neupro, used for Parkinson’s disease and restless legs syndrome.
- The dispute centered on later UCB patents covering rotigotine transdermal systems.
- Mylan’s Paragraph IV certification triggered the Hatch-Waxman litigation.
- The case involved small-molecule generic competition, not biosimilar substitution.
- UCB’s strongest protection was product-specific patch and formulation coverage.
- Mylan’s main defenses would involve non-infringement, invalidity, and possible design-around strategies.
- The filing created a statutory approval delay but did not itself establish the ultimate launch date.
- A public dismissal or settlement does not necessarily disclose the economic terms or agreed generic-entry date.
- Manufacturing complexity was a separate barrier to entry beyond patent protection.
FAQs About UCB v. Mylan and Neupro Generic Entry
What is the case number for UCB’s Neupro patent lawsuit against Mylan?
The action is UCB, Inc. v. Mylan Technologies Inc., No. 2:22-cv-00216, in the U.S. District Court for the District of Utah.
Was UCB v. Mylan a biologic patent case?
No. The case involved rotigotine, a small-molecule active ingredient, and proceeded under the ANDA Hatch-Waxman framework.
Could Mylan launch a generic Neupro patch before all UCB patents expired?
Only if Mylan obtained a license, prevailed in the litigation, secured an agreed entry date, or otherwise qualified for an earlier lawful launch.
Why are formulation patents important for transdermal patches?
A patch patent can cover the adhesive matrix, drug concentration, release profile, stability characteristics, or physical construction. These limitations can make a design-around difficult even after a compound patent expires.
Does an Orange Book patent listing prove that UCB’s patent is valid?
No. An Orange Book listing identifies a patent submitted to FDA in connection with an approved drug. Validity, enforceability, and infringement remain judicial questions.
References
-
U.S. District Court for the District of Utah. (2022). UCB, Inc. v. Mylan Technologies Inc., No. 2:22-cv-00216, docket materials.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Neupro prescribing information. https://www.accessdata.fda.gov/
-
21 U.S.C. § 355(j).
-
35 U.S.C. § 271(e)(2).
-
U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/
